Amazentis' Phase 1 clinical data show that Urolithin A is safe and effectively increases mitochondrial gene expression and modulates plasma metabolites linked to muscle function in healthy elderly individuals. The study's findings have significant implications for the treatment of age-related decline in mitochondrial and skeletal muscl...
Researchers at Amazentis SA and EPFL have discovered that urolithin A boosts mitochondrial function and reverses muscle aging. Oral administration of the compound enhances muscle strength and endurance in aged rodents.
Researchers have developed a novel therapeutic approach using nanomedicines called Navacims that can reprogram white blood cells to become regulatory cells capable of blunting autoimmune responses. The treatment has shown promising results in preclinical models of diabetes, multiple sclerosis, and rheumatoid arthritis.
Kolltan Pharmaceuticals presents substantial tumor shrinkage with KTN0158 in dogs with spontaneous mast cell tumors, with favorable results from non-clinical toxicology studies. The company plans to file an IND for the drug candidate in oncology this year.
A Phase 2 clinical trial demonstrates that AF-219, a selective and non-narcotic agent, significantly reduces daytime cough frequency by 75% compared to placebo. The study also shows improvements in secondary endpoints such as severity and urge to cough.
The Phase 1-2a clinical trial demonstrated a 92% objective response rate, including complete remissions in eight patients and partial remissions in four patients. Four out of seven evaluable patients with chemotherapy-refractory DLBCL achieved complete remissions, with durations ranging from 9 to 22 months.
A new study published in the Journal of Rheumatology shows that KRYSTEXXA significantly improves pain, physical function, and health-related quality of life in adult patients with refractory chronic gout. The treatment resulted in clinically meaningful improvements in these areas compared to placebo.
A study published in Ecology Letters found that early snow melt in the Colorado Rocky Mountains leads to lower flower availability, negatively affecting the growth rate of the Mormon Fritillary butterfly. Reduced flower availability per butterfly explained most of the observed variation in population growth rate.
A study published in the Journal of Thoracic Oncology found that a breath test using Metabolomx's colorimetric sensor array can detect lung cancer and differentiate between its types with high accuracy. The test shows promise as a non-invasive, rapid, and inexpensive companion diagnostic for early lung cancer detection.
The study showed that SB-509 was safe and well-tolerated, with no dose-limiting toxicities observed. Improvements in pain, numbness, and neurological symptoms were seen in approximately 50% of patients, with significant anecdotal improvements reported in neurologic exam scores and electrophysiologic testing.
Researchers have found that Sangamo's ZFN-modified cells are resistant to HIV infection, whereas control cells are infected. The treatment works by disrupting the CCR5 gene, a receptor required for HIV entry into immune cells. This approach has advantages over other drugs in development, which require constant antagonist presence.
The Phase I trial demonstrated the treatment's safety and efficacy in advanced Parkinson's disease, with statistically significant improvements in motor function and activities of daily living. The gene therapy approach offers a simpler alternative to deep brain stimulation, avoiding devices and requiring local anesthesia.
CK-1827452 selectively activates cardiac myosin, increasing contractility without changes in cellular calcium transient. The drug demonstrates improvement in cardiac function and output in a dog model of heart failure, supporting its therapeutic hypothesis.
The study reveals key connections between metabolic disease pathways and aging, identifying genes and mechanisms that can be targeted for drug discovery. Targeting these pathways may uncover novel therapeutic targets and drugs to treat metabolic diseases and potentially impact the progression of aging.
A Phase IIb trial found that VEGF-2 therapy led to significant improvements in exercise tolerance time and reduction in angina symptoms. The study suggests that the therapy may be associated with prolonged clinical benefits for patients with severe angina.
Paratek Pharmaceuticals has demonstrated disease protection in preclinical studies using non-antibacterial tetracycline compounds, which have no detectable antibacterial activity. These compounds show efficacy comparable to minocycline in reducing limb paralysis in the EAE model of MS.